[Skip to Content]
Dermatology

Five-Year Survival Among Patients With Advanced Skin, Renal, and Lung Cancer Treated With Nivolumab

JAMA Oncology
July 25, 2019 Audio Interview 19 min 25 sec
<title>Five-Year Survival Among Patients With Advanced Skin, Renal, and Lung Cancer Treated With Nivolumab</title>
Five-Year Survival Among Patients With Advanced Skin, Renal, and Lung Cancer Treated With Nivolumab
Download MP3

Interview with Suzanne L. Topalian, MD, author of Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
Read Transcript

Related

  1. Five-Year Survival Among Patients With Advanced Skin, Renal, and Lung Cancer Treated With Nivolumab

JN Learning™ from JAMA Network is your new home for CME and MOC from a source you trust. Earn AMA PRA Category 1 CME Credit™ from relevant articles, audio, and Clinical Challenge image quizzes, explore interactives and videos, and – depending on your specialty or state – have your MOC points automatically transferred to the relevant board. Learn more about CME

See More About

Dermatology Lung Cancer Melanoma Nephrology Targeted and Immune Cancer Therapy Oncology Skin Cancer Urology Urologic Cancer

Name Your Search

Save Search
Privacy Policy|Terms of Use

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Topics
State Requirements
Privacy Policy | Terms of Use
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue